Mothers' antiphospholipid antibodies during pregnancy and the relation to offspring outcome

Clinical and Experimental Rheumatology

Volumn 32, Issue 3, 2014, Pages 446-446

  Mekinian, Arsène ^a   Carbillon, L ^a   Nicaise Roland, P ^b   Rousseau, H ^c   Lachassinne, E ^a   Motta, M ^d   Vicaut, E ^c   Boinot, C ^e   Avcin, T ^f   De Carolis, S ^g   Rovere Querini, P ^h   Lambert, M ⁱ   Derenne, S ^j   Pourrat, O ^e   Chollet Martin, S ^b   Biasini Rebaioli, R ^d   Rovelli, R ^h   Lojacono, A ^d   Ambrozic, A ^f   Benbara, A ^a   Pierre, F ^e   Allegri, F ^d   Nuzzo, M ^d   Hatron, P Y ⁱ   Tincani, A ^d   Aurousseau, M H ^a   Boffa, M C ^a   Fain, O ^a   more..

^a UNIVERSITÉ PARIS 13   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY OF BRESCIA   (Italy)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^g CATHOLIC UNIVERSITY   (Italy)

^h San Rafaele Scientific Institute   (Italy)

ⁱ UNIV LILLE   (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; APGAR SCORE; BODY HEIGHT; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HIGH RISK PREGNANCY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; NEWBORN; NEWBORN DISEASE; PATIENT MONITORING; PREDICTIVE VALUE; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; SMALL FOR DATE INFANT;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; RISK FACTORS;

EID: 84901845869     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. MEKINIAN A, LACHASSINNE E, NICAISE-ROLAND P et al.: European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis 2013 Feb; 72: 217-22.
2. RUFFATTI A, TONELLO M, CAVAZZANA A et al.: Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123: 482-7.
3. BOFFA MC, AUROUSSEAU MH, LACHASSINNE E et al.: European register of babies born to mothers with antiphospholipid syndrome. Lupus 2004; 13: 713-7.
4. RUFFATTI A, CALLIGARO A, HOXHA A et al.: Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 2010; 62: 302-7.
5. LOCKSHIN MD, KIM M, LASKIN CA et al.: Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-8.
6. RUFFATTI A, SCAPINELLO MP, TONETTO S et al.: Trends in immunoglobulin G anticardiolipin antibodies in ten successful heparin-treated pregnancies. Rheumatol Int 1996; 16: 15-8.
7. RUFFATTI A, TONELLO M, VISENTIN MS et al.: Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology 2011; 50: 1684-9.
8. CARBILLON L, UZAN M, UZAN S: Pregnancy, vascular tone, and maternal hemodynamics: a crucial adaptation. Obstet Gynecol Surv 2000; 55: 574-81.
9. AMINO N, TANIZAWA O, MIYAI K et al.: Changes of serum immunoglobulins IgG, IgA, IgM, and IgE during pregnancy. Obstet Gynecol 1978; 52: 415-20.
10. YASUHARA M, TAMAKI H, IYAMA S, YAMAGUCHI Y, TACHI J, AMINO N: Reciprocal changes in serum levels of immunoglobulins (IgG, IgA, IgM) and complements (C3, C4) in normal pregnancy and after delivery. J Clin Lab Immunol 1992; 38: 137-41.
11. CARBILLON L, CHALLIER JC, ALOUINI S et al.: Uteroplacental circulation development: Doppler assessment and clinical importance. Placenta 2001; 22: 795-9.